Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.005
-0.005 (-0.50%)
Mar 31, 2025, 2:30 PM EDT - Market open

Opus Genetics Statistics

Total Valuation

Opus Genetics has a market cap or net worth of $45.19 million. The enterprise value is $9.18 million.

Market Cap 45.19M
Enterprise Value 9.18M

Important Dates

The next confirmed earnings date is Monday, March 31, 2025, before market open.

Earnings Date Mar 31, 2025
Ex-Dividend Date n/a

Share Statistics

Opus Genetics has 44.96 million shares outstanding. The number of shares has increased by 14.60% in one year.

Current Share Class 44.96M
Shares Outstanding 44.96M
Shares Change (YoY) +14.60%
Shares Change (QoQ) +1.23%
Owned by Insiders (%) 5.07%
Owned by Institutions (%) 8.17%
Float 40.12M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.00
Forward PS 3.78
PB Ratio 0.77
P/TBV Ratio 1.34
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.10
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.63

Current Ratio 6.63
Quick Ratio 6.56
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -22.19

Financial Efficiency

Return on equity (ROE) is -64.30% and return on invested capital (ROIC) is -43.56%.

Return on Equity (ROE) -64.30%
Return on Assets (ROA) -38.95%
Return on Invested Capital (ROIC) -43.56%
Return on Capital Employed (ROCE) -85.93%
Revenue Per Employee $598,643
Profits Per Employee -$1.94M
Employee Count 14
Asset Turnover 0.18
Inventory Turnover n/a

Taxes

Income Tax -2,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -49.30% in the last 52 weeks. The beta is 0.25, so Opus Genetics's price volatility has been lower than the market average.

Beta (5Y) 0.25
52-Week Price Change -49.30%
50-Day Moving Average 1.08
200-Day Moving Average 1.29
Relative Strength Index (RSI) 46.34
Average Volume (20 Days) 272,015

Short Selling Information

The latest short interest is 685,446, so 1.52% of the outstanding shares have been sold short.

Short Interest 685,446
Short Previous Month 703,397
Short % of Shares Out 1.52%
Short % of Float 1.71%
Short Ratio (days to cover) 3.44

Income Statement

In the last 12 months, Opus Genetics had revenue of $8.38 million and -$27.19 million in losses. Loss per share was -$1.09.

Revenue 8.38M
Gross Profit -15.39M
Operating Income -29.47M
Pretax Income n/a
Net Income -27.19M
EBITDA -29.47M
EBIT -29.47M
Loss Per Share -$1.09
Full Income Statement

Balance Sheet

The company has $36.64 million in cash and n/a in debt, giving a net cash position of $36.64 million or $0.81 per share.

Cash & Cash Equivalents 36.64M
Total Debt n/a
Net Cash 36.64M
Net Cash Per Share $0.81
Equity (Book Value) 34.30M
Book Value Per Share 1.31
Working Capital 34.30M
Full Balance Sheet

Cash Flow

Operating Cash Flow -13.59M
Capital Expenditures n/a
Free Cash Flow -13.59M
FCF Per Share -$0.30
Full Cash Flow Statement

Margins

Gross Margin -183.63%
Operating Margin -351.68%
Pretax Margin -324.47%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Opus Genetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -14.60%
Shareholder Yield -14.60%
Earnings Yield -59.35%
FCF Yield -29.66%

Analyst Forecast

The average price target for Opus Genetics is $8.00, which is 696.02% higher than the current price. The consensus rating is "Strong Buy".

Price Target $8.00
Price Target Difference 696.02%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) 20.17%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Opus Genetics has an Altman Z-Score of 0.37 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.37
Piotroski F-Score 1